-- FactSetが調査したアナリストによると、Insulet（PODD）の平均レーティングは「オーバーウェイト」、平均目標株価は329.87ドルです。 （は、北米、アジア、ヨーロッパの主要銀行および調査会社による株式、商品、経済に関する調査レポートを配信しています。調査レポート提供者の方は、こちらからお問い合わせください：https://www..com/contact-us）
Price: $151.07, Change: $-16.46, Percent Change: -9.83%
Related Articles
Research
Research Alert: Cgnx Posts Q1 Beats On Broad-based Demand; Guides Above Consensus
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:CGNX delivered solid Q1 2026 results with revenue of $268M (+24% Y/Y), beating consensus by $22M, while adjusted EPS of $0.34 (+113% Y/Y) exceeded expectations by $0.09. Margin expansion continued with adjusted EBITDA margin reaching 26.9% (+1,010 bps Y/Y) and operating margin surging to 22.3% (+1,020 bps), demonstrating exceptional operational leverage. We believe this validates the diversification strategy and suggests industrial automation recovery is gaining momentum. Strong cash generation produced $42.3M in free cash flow (+11% Y/Y), while the company returned $113M to shareholders and maintains $622M in cash with zero debt. Q2 guidance indicates continued momentum with revenue expected at $280M-$300M and adjusted EPS of $0.40-$0.44 (+68% Y/Y at midpoint), above consensus of $0.30. We see the combination of technology leadership, operational excellence, and end-market diversification positioning CGNX well for sustained outperformance through the automation cycle.
$CGNX
Research
Research Alert: Albemarle Corporation Posts Strong Q1 Beat On Lithium Recovery
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Albemarle delivered strong Q1 results with net sales of $1.43B (+33% Y/Y, 8.4% above consensus) and adjusted EPS of $2.95 vs. a loss of $0.18 in the prior year, beating consensus by $1.64. Adjusted EBITDA surged 148% Y/Y to $664M, demonstrating significant operational leverage as lithium pricing recovered. The Energy Storage segment led recovery with sales of $891M (+70% Y/Y) driven by pricing improvements (+51%) and volume growth (+14%), while adjusted EBITDA jumped 196% to $551M. Management provided 2026 outlook scenarios based on lithium pricing. Assuming the FY 25 average (~$10/kg LCE) projects $4.1B-$4.3B sales and $0.9B-$1.0B adjusted EBITDA, while the Q1 2026 average (~$20/kg LCE) suggests $5.7B-$6.0B sales and $2.4B-$2.6B adjusted EBITDA. We believe ALB's balance sheet optimization through $1.3B debt reduction and $648M in divestiture proceeds strengthens financial flexibility. ALB remains on track for $100M-$150M in annual cost improvements while maintaining disciplined capex guidance of $550M-$600M.
$ALB
Research
Research Alert: Sun Life Posts Modestky Higher Q1 Operating Eps
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Sun Life Financial posted Q1 2026 underlying EPS of $1.89, up 4% Y/Y, matching consensus but missing our $1.93 estimate. Reported results were significantly impacted by $310M in one-time charges, including $165M for SLC Management acquisitions and $145M legal settlement. Asia remained a standout performer with underlying net income rising 17% Y/Y to $216M, driven by strong Hong Kong sales momentum and 41% growth in individual insurance sales, reinforcing its position as a key growth engine. Canada delivered solid 7% Y/Y growth in underlying net income to $370M, supported by higher fee income from AUM growth. Asset management results were mixed with underlying net income declining 7% Y/Y to $363M as lower catch-up fees offset solid MFS performance, while net outflows widened to $17.8B from $6.2B. We view the underlying ROE improvement to 18.6% from 17.7% as encouraging, reflecting effective capital deployment despite operational headwinds.
$SLF